Trinity Biotech plc
Trinity Biotech plc (TRIB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
trib · stock forecast · 4 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.68
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.71 | ↑ 5.00% |
1-day model range: $0.71–$0.72. Peak: $0.72 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TRIB · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2016-10-04 | Stephens & Co. | Downgrade ↓ | Overweight→Equal Weight |
| 2015-05-29 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2014-04-29 | Roth Capital | Upgrade ↑ | Neutral→Buy |
| 2013-03-05 | Craig-Hallum | Maintains | Buy→Buy |
| 2013-01-21 | Roth Capital | Downgrade ↓ | Buy→Neutral |
| 2012-12-11 | CJS Securities | Maintains | Market Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Trinity Biotech plc (TRIB) stock. Of the recent 6 rating actions, 1 were upgrades and 2 were downgrades. 4 analysts currently cover TRIB.
Analyst Recommendation Trends
TRIB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$75M
↑ 20.2% YoY
Revenue Next Year
$58M
↓ 22.1% YoY
EPS This Year
$-3.55
EPS Next Year
$-2.95
↓ 16.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast TRIB EPS of $-3.55 for the current fiscal year, based on estimates from 1 analysts. The TRIB revenue forecast is $75M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TRIB stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TRIB price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The TRIB short-term stock prediction for tomorrow is $0.71 (+5.00%).
Trinity Biotech plc trades on NASDAQ under the ticker TRIB. The TRIB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
TRIB forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month TRIB price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.68.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.